Phase II LSALT Peptide Trial Expands with Three Turkish Hospitals for Cardiac Surgery-Related AKI

Arch Biopartners, a clinical-stage company, has expanded its Phase II clinical trial for LSALT peptide to include three new Turkish hospitals, bringing the total number of participating sites to seven across Turkey and Canada. The LSALT peptide is a novel drug candidate designed to prevent and treat inflammation injuries in vital organs such as the kidneys, lungs, and liver.

The Phase II trial specifically targets acute kidney injury associated with cardiac surgery (CS-AKI), a condition often resulting from ischemia-reperfusion injury (IRI), which involves a reduction in blood flow and oxygen to the kidneys, leading to cell damage. The trial is an international, multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the effectiveness of LSALT peptide in 240 patients who have undergone on-pump cardiac surgery. The primary goal is to measure the percentage of patients developing AKI within a week of surgery, as defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria.

Arch scientists and their partners have demonstrated the peptide's ability to prevent IRI in the kidneys through pre-clinical models. Their findings were published in the journal Science Advances, highlighting the peptide's unique mechanism of action as a Dipeptidase-1 (DPEP-1) inhibitor. Unlike traditional anti-inflammatory drugs, LSALT peptide targets the novel adhesion receptor DPEP-1, which is implicated in organ inflammation.

The clinical details of the Phase II trial can be found on the clinicaltrials.gov website under the title "Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery."

Arch Biopartners is dedicated to developing new drug candidates that mitigate inflammation in the lungs, kidneys, and liver through the DPEP-1 pathway. The company's focus is on addressing unmet needs in common injuries and diseases characterized by organ inflammation.